



Prifysgol Cymru

Y Drindod Dewi Sant

University of Wales

Trinity Saint David

Title: Assessment 2: Portfolio: Brand Extension

Programme: Master of Business Administration

Module: Marketing Management

Module code: LCMB7024

Submission Date: 28/04/2025

Submitted To:

Dr. Laila Maazouz

University of Wales Trinity Saint David

Submitted By:

Md. Reza

ID: 2421692

Table of Contents

Introduction.....	3
Brand Extension (VR).....	4
Description of the VR Solution	4
Rationale for the Extension.....	4
Alignment with AstraZeneca’s Brand Values.....	5
Market Gap Fulfilment and Value Addition	5
STP – Segmentation, Targeting, and Positioning	6
Segmentation.....	6
Targeting.....	7
Positioning	7
Customer Personal Profile.....	8
Demographic Characteristics	8
Psychographic Characteristics.....	9
Marketing Mix Strategy – 7Ps	9
Conclusion.....	13
Reference List.....	14

Introduction

AstraZeneca PLC is a Cambridge, United Kingdom-based, globally renowned biopharmaceutical company. The company operates in over 100 countries and is a science-led innovation company with a commitment to improving health in the world through the development of prescription medicines. AstraZeneca is one of the leading pharmaceutical companies in the industry and plays a key role in the creation of modern technologies for the sake of research and development of medicines (Paley, 2021).

The company operates in oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies. These critical areas where AstraZeneca is focused are strategic areas that address some of the most challenging and prevalent diseases worldwide (Grewal, and Levy, 2022). From a clinical science, digital health and patient engagement perspective, onlinehealth's strategy is to be integrated to improve innovation, underlining its vision to become the basis for transforming patient outcomes.

The proposed brand extension of this paper is a Virtual Reality (VR) solution to manage pain and anxiety. This is a digital innovation that will complement current treatments, especially in hospitals and other chronic care settings. Therefore, AstraZeneca can combine VR into patient care, expand the company's offerings outside the pharmacological solutions, and move in line with the company's patient-centric approach and digital transformation agenda (Pepels, 2021). This initiative is based on the organisation's consistent drive for novel, non-invasive, holistic health solutions that address patients' physical and psychological needs.

Brand Extension (VR)

Description of the VR Solution

A Virtual Reality (VR) therapy proposed brand extension was planned to help patients deal with pain and anxiety. This digital solution provides such immersive therapeutic environments as calming natural scenes, guided breathing sessions, mindfulness exercises, and cognitive distraction experiences. The VR tool is designed to be tailored for different clinical settings and to be used even in procedures, hospital recovery periods, or outpatient treatment sessions. It primarily serves as a means of tying patients' sensory perception and cognitive focus to factors that reduce discomfort and psychological distress (Doole, Lowe, and Kenyon, 2019).



Figure 1: AstraZeneca HQ in Cambridge UK (Wikipedia, 2020).

Rationale for the Extension

A growing and substantial amount of clinical research supports the introduction of VR into AstraZeneca's portfolio. Indeed, VR has been proven in multiple studies to reduce patients' perceived pain levels and anxiety in environments such as a cancer ward,

intensive care unit and chronic pain clinic. As society calls for increasingly more non-pharmacological interventions, and as they fear outdated usage and misuse of opioids, offering alternative therapeutic options is more important than ever (Wichmann, et al., 2022). The introduction of the technology, however, also enables the acceleration of digital health trends, in particular post-pandemic healthcare innovation and technological advancements, creating a favourable environment for VR-based applications.

Alignment with AstraZeneca's Brand Values

Aligned with AstraZeneca's long-standing commitment to science-led innovation, excellence in patient care and digital transformation, this extension. Integration of VR into the treatment pathway further shows the patient-centric tone of the company and meets the changing dynamics of healthcare (Andrews, and Shimp, 2018). The VR represents AstraZeneca's conviction in a holistic, integrated approach to care as well as the company's aspiration to become a pioneer in going beyond simple pharmacological products.

Market Gap Fulfilment and Value Addition

However, there is still an obvious gap in the pharmaceutical industry for digital solutions to address the emotional and psychological needs of treatment. To fill this gap, this VR extension brings to the overall patient experience and complements pharmaceutical interventions (Aaker, and Moorman, 2023). It provides another differentiator in a very competitive space, and it supports AstraZeneca's current perception as a forward-thinking, innovative healthcare company. Moreover, it gives a company more opportunities to liaise with hospitals and doctors beyond just the medicines, and supply tools that improve patient satisfaction and maximise outcomes (Hisrich, and Ramadani, 2018).

STP – Segmentation, Targeting, and Positioning



Figure 2: Segmentation, Targeting and Positioning (STP) (Kampamba, 2015).

Segmentation

AstraZeneca’s proposed solution of VR strategy would be applied to patient groups in an explicit fashion according to the segmentation techniques, based on demographics, geography, psychology, and behaviour.

Demographic Segmentation:

The main demographic groups of interest are adults and adolescents who are taking moderate to severe pain or anxiety drugs. Everyone from those with chronic illness, such as cancer, arthritis or fibromyalgia, to those who are scheduled for a surgical procedure or coping with repeated medical procedures (Cao, 2024).

Geographic Segmentation:

Modules for the initial launch are best developed for developed markets such as the U.K., European Union, and North America. Besides, these regions have access to the latest healthcare infrastructure, full access to digital health platforms and soaring investment in medical technology integration.

Psychographic Segmentation:

Typically, targeted individuals are health-conscious and willing to seek holistic and non-pharmacological treatment (Morgan, et al., 2019). So they value innovation, prefer to minimise the use of medication, and go looking for solutions complementary to life and mental well-being.

Behavioural Segmentation:

This segment includes patients who are known for high adherence to treatment regimens, frequent engagement with healthcare services, and those who seek tools to manage stress and discomfort while or after clinical procedures (Kotler, Keller, and Ang, 2018). Because of this, these patients are likely to be motivated towards comfort, control, and an improved recovery experience.

Table 1: Segmentation variables (Self-Made).

Targeting

Following segmentation analysis, an ideal target market includes hospital inpatients being treated for acute conditions and outpatients being treated for chronic conditions. High levels of anxiety and discomfort are a part of these groups, but they may not receive the type and level of psychological support that they need while using standard clinical pathways (Gu, 2020). The tactics for targeting adopt a concentrated marketing approach as it is focused on a well-defined segment where there are clear and unmet needs.

The main customers are hospitals, rehabilitation centres and specialist clinics. In future phases, the solution can be marketed to healthcare providers through broader patient experience enhancement and to individual patients in an out-of (B2C) digital health platform (Deepak, and Jeyakumar, 2019). The targeting also fits with AstraZeneca's wider ongoing partnerships within the healthcare ecosystem, with medical professionals, patient groups or technology providers.

Positioning

Instead, the VR brand extension will be used to position itself as a scientifically validated, digital therapeutic that complements AstraZeneca's pharmacological offerings (Kotabe, and Helsen, 2022). Thus, the positioning statement can be stated as follows:

“AstraZeneca VR Therapy: Raising patient care to new heights through immersive, clinically-enabled, digital solutions, alleviating pain and anxiety to promote well-being throughout treatment.”

This positions the brand, in a broad sense, as a committed one to innovation, emotional well-being and integrated patient care. Unlike other competing companies, focusing solely on medication, AstraZeneca differentiates itself by addressing both the physical and psychological aspects of healing (Aaker and Moorman, 2023). Empathy, empowerment and clinical impact, the theme of the solution, enhance the reputation of AstraZeneca as a holistic healthcare innovator.

Customer Personal Profile

Thus, a sophisticated, detailed customer persona has been developed for the ideal user to effectively tailor the Virtual Reality (VR) brand extension. This persona not only is a good way of giving the demographic and psychographic characteristics of the target market, but it also explains their motivations and needs (Ennew, Waite and Waite, 2024).




Figure 3: Customer Persona Overview (Self-made).

Persona Overview: Emma

Emma is a 45-year-old marketing consultant, lives in a metropolitan area in the United Kingdom, which makes her the representative customer. For over a decade, she has had chronic lower back pain due to a spinal condition. She has had regular physiotherapy and receives pain medicine, but is getting more worried about the long-term effects of the pharmacological treatments that she is seeking alternatives that are completely non opioid that work on the physical, as well as the emotional.

Demographic Characteristics

Age: 45 years old

Gender: Female

Income: Moderate-to-high income bracket

Occupation: Marketing consultant (full-time)

Education: Postgraduate degree in business

Location: Urban area in the United Kingdom

Healthcare Access Utilises both public and private healthcare services. Technology Use, Digitally literate and open to innovation. Actively engaged or manages a chronic condition and looks for new age, non-invasive solutions. Lifestyle, Health-conscious, financially independent, and receptive to digital therapeutic tools.

The demographic segment that they are referring to — professionals earning a living, trained in industrial culture, independent, urban population — is naturally the receptive audience to innovative solutions in the healthcare area (Alsem, 2023). Emma is a consumer with the willingness, motivation and ability to interact with AstraZeneca's Virtual Reality brand extension aimed at relieving pain and anxiety. Hence, her profile is in line with the strategic targeting of this product.

Psychographic Characteristics

Everything aligned, and Emma's well-being has been Emma's. She uses regular yoga, mindfulness and holistic therapies. She prefers non-invasive tools that are as convenient as possible for her and that she can easily include in her existing routine (Marshall, and Johnston, 2019). She is fascinated with therapies that decrease dependence on pharmaceuticals and is a seeker of autonomy in her condition. Core to the decision making is comfort, control and personalising her healthcare experience.

For VR brand extension, this customer profile takes the stance of an emotional well-being, modernity, technology empowerment-based marketing approach, which is defined in the VR brand extension value proposition.

Marketing Mix Strategy – 7Ps

A carefully designed marketing mix strategy is to be adapted to the sector of healthcare sector for the proposed Virtual Reality (VR) solution for pain and anxiety management. In this attempt, integration of digital therapeutics into AstraZeneca's service offering depends on the alignment across all 7Ps, including X and Ps.



Figure 4: 7 P's Marketing Mix (Wang, 2023).

Product

It is a medical-grade VR headset with a curated set of immersive experiences from pain relief to anxiety reduction preloaded. Guided meditations, nature-based simulations and interactive visual environments scientifically proven to be therapeutic for their users are included in the software (Park, 2020). The designed product is patient-friendly for easy usage by patients across different age groups and is intended to be deployed in hospitals, outpatient clinics and rehabilitation centres. Besides offering access to clinical focus groups and usage analytics, this digital medical tool is

also enhanced by a healthcare provider's access to usage analytics and clinical feedback features.

Price

There will be a tiered pricing strategy aimed at various customer segments. For business-to-business (B2B) groups, such as hospitals and private healthcare centres, pricing will be determined through licensing agreements as well as through bulk procurement. Such agreements may also include additional support services like training and maintenance. B2C future model may be through healthcare apps where the target is individual patients and caregivers interested in extra therapies on a monthly or annual basis (Kinicki, and Williams, 2020). With this flexible pricing offering, institutions can afford it, and individuals can get access to the course.

Place

The distribution strategy includes partnering with hospitals, private clinics, pain management centres, in addition to mental health providers. Additionally, the product will be integrated into the digital health ecosystems as secure health care platforms and apps. By distributing this solution across multiple channels, they make sure that the VR solution is usable in both inpatient as well as outpatient clinics (Czinkota *et al.*, 2021). It may also be useful for future deployment, such as direct-to-consumer delivery via online healthcare marketplaces, for the wider adoption in various remote and home care settings.

Promotion

Awareness among healthcare professionals and decision makers will be a priority of promotional efforts. Some of the strategies include displaying the VR solution at medical technology conferences, publishing first results in the area proven by clinical journals, and working with associations related to the treatment of pain and anxiety (Singh, and Shukla, 2024). LinkedIn, YouTube and other professional medical networks will be targeted for Digital marketing campaigns that will be directed to healthcare administrators and patient communities. Furthermore, there will be partnerships with pain-related charities and advocacy groups to continue to trust, visibility and community engagement.

Process

On the process end, we'll set up a streamlined process of product onboarding and using the product. Beyond providing a complete installation support package, including clinic training and system integration aid, the system was designed to give healthcare institutions the entire range of operational support after it's shipped. The patient record systems, which the VR software will be compatible with, will also enable clinicians to know the session frequency and its effectiveness (Malhotra, Nunan, and Birks, 2020). Brief guided tutorials will be introduced to patients who will be supported by staff during initial sessions to ensure ease and comfort of use. AstraZeneca's customer care team will provide technical troubleshooting support to keep service quality constant.

People

This service will only be successful if it relies on the involvement of trained healthcare professionals. The VR experience will be enabled by nurses, physiotherapists and psychologists attending as facilitators of the VR experience to offer guidance as well as monitor use (Voeth, and Herbst, 2021). Training, technical assistance and user feedback channels will be provided by AstraZeneca's in-house support team. Collaboration with external software developers and digital partners will be overseen internally by the staff to ensure product innovation and performance standards are still being maintained.

Physical Evidence

The physical evidence of the service is the VR headset itself, which is packaged in professional, medical-grade packaging that is consistent with AstraZeneca's brand identity (Dianlin and Ruokai, 2025). The user interface of the VR system will be clean, intuitive and will carry AstraZeneca's branding and compliance certification logos. In addition, primary materials including pamphlets outlining instruction, case studies, poster(s) for a clinic and a demo unit on site will further attest to the legitimacy and value of the service. These tangible components therefore offer reassurance to the clinicians and the patients that the product is safe, efficacious and professional in terms of its use.

Conclusion

AstraZeneca PLC is strategically and timely introducing a Virtual Reality (VR) solution for pain and anxiety management for its brand. This extension capitalises on the emerging technologies in the field of healthcare and at the same time digital innovation and patient-focused care, which has enabled this extension to extend treatment outcomes beyond the traditional pharmacological approach (Zimmerman, and Blythe, 2017). VR solution is a completely immersive and evidence-based therapeutic experience addressing the pain or anxiety-inducing treatments experienced by patients.

This initiative has a strong link with AstraZeneca's ambition to bring to life-changing medicines and improve the lives of patients through innovation. The VR therapy proposed is an example of the company's endeavour at holistic healthcare through a convergence of physical and emotional treatment elements (Tulum, Andreoni, and Lazonick, 2022). AstraZeneca's approach to this forward-thinking and its ability to grow its influence in the evolving digital health landscape is also reflected in this.

It recommends that AstraZeneca roll out a controlled pilot programme in high hospital networks in the United Kingdom and some European markets. Real-time testing, feedback on patient collection and improving the model of service delivery would be enabled. Despite them, a phased global rollout could be done in the markets with existing digital infrastructure and a supportive healthcare policy environment, if a product is first successful with initial evaluation (Dibb, et al., 2019). Using this orchestrated enlargement, the extension of the VR brand creates an organised impression in the AstraZeneca therapeutic ecosystem and helps contribute to the company's posture as a leader in modern healthcare innovation.

Reference List

- Dibb, S., Simkin, L., Pride, W.M. and Ferrell, O.C., (2019) *Marketing: Concepts and strategies*. Cengage Learning EMEA.
- Doole, I., Lowe, R. and Kenyon, A., (2019) *International marketing strategy: analysis, development and implementation*. Cengage Learning.
- Kotabe, M.M. and Helsen, K., (2022) *Global marketing management*. John Wiley & Sons.
- Kotler, P., Keller, K.L. and Ang, S.H., (2018) *Marketing management: an Asian perspective*. Pearson.
- Marshall, G.W. and Johnston, M.W., (2019) *Marketing management*. McGraw-Hill.
- Park, S., (2020) *Marketing management* (Vol. 3). Seohee Academy.
- Hisrich, R.D. and Ramadani, V., (2018) *Entrepreneurial marketing: a practical managerial approach*. Edward Elgar Publishing.
- Paley, N., (2021) *The manager's guide to competitive marketing strategies*. Routledge.
- Malhotra, N.K., Nunan, D. and Birks, D.F., (2020) *Marketing research*. Pearson UK.
- Singh, J. and Shukla, P. (2024) *Brand Management: Principles and Applications for Effective Branding*. Kogan Page Publishers.
- Voeth, M. and Herbst, U., (2021) *Marketing-Management*. Schäffer-Poeschel.
- Zimmerman, A. and Blythe, J. (2017) *Business to business marketing management: A Global Perspective*. Routledge.
- Tulum, Ö., Andreoni, A. and Lazonick, W., (2022) *From financialisation to innovation in UK Big pharma: AstraZeneca and GlaxoSmithKline*. Cambridge University Press.